--- a
+++ b/clusters/3009knumclusters/clust_112.txt
@@ -0,0 +1,269 @@
+Ongoing serious, non-healing wound, ulcer, or bone fracture
+History of serious or non-healing wound, ulcer, or bone fracture
+Serious or non-healing wound, skin ulcer, or bone fracture
+Prior osteoporotic fracture
+Serious nonhealing wound, ulcer, or bone fracture
+Serious non-healing wound, ulcer, or bone fracture within 6 months prior to enrollment
+Patients who have undergone major surgery or trauma within 28 days prior to the first dose of investigational product and/or present with any non-healing wound, fracture, or ulcer are NOT eligible for participation; procedures such as catheter placement not considered to be major surgery
+Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
+Serious, non-healing wound, active ulcer, or untreated bone fracture
+Serious, non-healing wound, ulcer, or bone fracture.
+Evidence of a significant uncontrolled concomitant disease of the nervous system, pulmonary, autoimmune, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture
+Serious or non-healing wound, peptic ulcer, or bone fracture within 28 days prior to initiation of study treatment;
+Patients with serious or non-healing wound, ulcer, or bone fracture
+Prior major surgery or fracture within 3 weeks prior to randomization or presence of any non-healing wound.
+Patients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
+Serious or non-healing wound, ulcer, or bone fracture.
+Presence of a non-healing wound, or non-healing ulcer, (that is not tumor related) or bone fracture
+Any patient with a current non-healing wound, bone fracture, or skin ulcer is excluded
+Patients with serious non-healing wound, ulcer, or bone factor; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
+Presence of serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
+Serious, non-healing wound; active ulcer; or untreated bone fracture
+Presence of any non-healing wound, fracture, or ulcer within 28 days prior to study registration.
+Patients with serious or non-healing wound, ulcer, or bone fracture.
+Patients who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment are not eligible
+Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment; participants with HIV infection will be eligible provided they meet the criteria; participants with known hepatitis B infection should be screened for active disease prior to study participation; participants with known hepatitis C infection must not be actively receiving treatment for the infection\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
+Ongoing serious, non-healing wound, ulcer, or bone fracture.
+Have active poor wound healing (delayed healing, wound infection or fistula)
+Patients with a serious non-healing wound, active ulcer, or untreated bone fracture
+Presence of non-healing wound, non-healing ulcer, or bone fracture
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Any severe or poorly controlled systemic disease (e.g., hypertension; clinically significant cardiovascular, pulmonary, or metabolic disease, disorders of wound healing, ulcer or bone fracture)
+Serious, non-healing wound, ulcer, or bone fracture
+Serious, non-healing wound or ulcer; bone fracture within 3 months prior to study entry
+Serious or non-healing wound, ulcer or bone fracture
+History or evidence of arterial thrombotic or hemorrhagic disorders within 3 months before proposed start of treatment, non-healing wound, ulcer, or bone fracture
+Patients who have a non-healing wound, ulcer, or bone fracture.
+Serious non-healing wound, ulcer or bone fracture
+Serious, non-healing wound, active ulcer, or untreated bone fracture.
+Non-healing wound, ulcer, non-healing traumatic bone fracture, or abscess within 30 days of enrollment\r\n* Nondisplaced, uncomplicated pathologic fracture due to tumor may be eligible provided adequately treated with radiation, surgery or other treatments with full recovery based upon investigator assessment
+Has a known history of non-healing wounds or ulcers, or bone re-fractures within 3 months of fracture
+Non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the underlying neoplasm;
+Serious, non-healing wound, ulcer, or bone fracture
+Serious, non-healing wound, ulcer, or bone fracture.
+Serious non-healing wound, ulcer or bone fracture
+Non-healing wound, ulcer, or bone fracture
+Patients who have serious, non-healing wound, ulcer, or bone fracture
+Serious, non-healing wound, ulcer, or bone fracture.
+have any non-healing wound, fracture, or ulcer within 28 days prior to the planned start of study treatment;
+(Bevacizumab-related exclusion) History of abdominal fistula or gastrointestinal perforation within 6 months prior to the first study treatment. Serious, non-healing wound, active ulcer, or untreated bone fracture (adjuvant trials: bone fractures must be healed)
+Serious non-healing or dehiscing wound, active ulcer, or untreated or non-healing bone fracture
+FOR ALL PHASES (Ib AND II): Non-healing wound or ulcer
+Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement are not considered to be major surgery)
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Serious or non-healing wound, ulcer, or bone fracture.
+Serious, non-healing wound, active ulcer, or untreated bone fracture, including tumor-related pathological fracture
+Presence of a non-healing wound, non-healing ulcer or bone fracture
+History of abdominal fistula or gastrointestinal perforation =< 6 months before cycle 1, day 1; serious non-healing wound, active ulcer, or untreated bone fracture (adjuvant trials: bone fractures must be healed)
+Non-healing wound, ulcer, or bone fracture
+Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
+Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
+Serious, non-healing or dehiscing wound or active ulcer
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Participant has a serious, non-healing wound, ulcer, or bone fracture
+At least 4 weeks must have elapsed since any surgeries, with evidence of completed wound healing
+Active wound, a serious or non-healing wound, an active ulcer or untreated bone fracture
+Non-healing wound, bone fracture, or skin ulcer
+mCRPC EXPANSION COHORT: Other clinically significant disorders such as:\r\n* Active infection requiring intravenous treatment within 7 days of starting protocol treatment\r\n* Serious non-healing wound/ulcer/bone fracture (excluding stable compression fracture) within 28 days before the first dose of study treatment
+No evidence of a history of wound healing complications prior to study enrollment
+Increased risk of wound dehiscence or presence of non-healing wounds
+The patient has a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
+Serious, non-healing or dehiscing wound
+Non-healing wound, ulcer, or bone fracture
+REGORAFENIB EXCLUSION CRITERIA: Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Non-healing wound, active peptic ulcer or bone fracture
+The patient has a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment
+Presence of a non-healing wound, non-healing ulcer, or benign bone fracture (patients with stress insufficiency fractures e.g. from osteoporosis or pathological fracture from tumor are eligible for study)
+Serious or nonhealing wound, ulcer, bone fracture, or osteonecrosis of the jaw
+Subject has a serious, non-healing wound, ulcer, or bone fracture
+Incomplete wound healing
+Presence of any non-healing wound, fracture, or ulcer
+Must not exhibit a non-healing wound or any skin breakdown
+Patients who have serious, non-healing wound, ulcer, or bone fracture
+Major surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
+Serious, non-healing wound, active ulcer, or untreated bone fracture
+Serious non-healing wound, ulcer, or bone fracture
+Serious, non-healing wound, ulcer, or bone fracture
+Serious non-healing wound, active peptic ulcer, or untreated bone fracture
+Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
+Serious non-healing wound, non-healing ulcer, or bone fracture
+Serious or non-healing wound, ulcer or bone fracture
+The patient has a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to first dose of protocol therapy
+Serious, non-healing wound, active ulcer, or untreated bone fracture
+A serious, non healing wound, ulcer, or bone fracture
+Serious, non-healing wound, active ulcer, or untreated bone fracture; any bone fractures must be healed
+Serious, non-healing wound, ulcer, or bone fracture
+Non-healing wound(s) or ulcer(s) except for ulcerative lesions caused by the underlying neoplasm;
+Non healing wound, ulcer or bone fracture
+Non-healing serious wound, ulcer, or bone fracture unrelated to the primary tumor
+Non?healing wound, ulcer, or bone fracture
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Presence of a serious nonhealing wound, ulcer, or bone fracture
+Ongoing significant, uncontrolled medical condition including: o Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
+Other clinically significant disorders such as:\r\n* Active uncontrolled infection requiring intravenous systemic treatment within 14 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib if there were no wound healing complications or within 6 months of the first dose of cabozantinib if there were wound complications\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications\r\n*** In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
+History of serious or non-healing wound, ulcer, or bone fracture
+Evidence of inadequate wound healing
+Patients with a non-healing wound, fracture, or ulcer
+Non-healing wound, ulcer or bone fracture
+Patients with serious non-healing wound, ulcer, or bone fracture within 28 days before registration; patients should not have had any major surgical procedures within 28 days of registration
+Serious, non-healing wound, active ulcer, or untreated bone fracture
+Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment\r\n* Serious non-healing wound/ulcer/bone fracture\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\r\n* History of major surgery within 4 weeks or minor surgical procedures within 1 week before randomization
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Prior major surgery within the previous 28 days of study registration and/or presence of any non-healing wound, fracture, or ulcer
+Subjects with a non-healing serious wound, ulcer, or bone fracture unrelated to the primary tumor
+Patients who have a serious or non-healing wound, ulcer, or bone fracture at the time of study enrollment are not eligible
+Serious or non-healing wound, ulcer or bone fracture
+Serious non-healing wound, ulcer, bone fracture, or abscess
+Serious, non-healing wound, ulcer, or bone fracture
+Patients with a serious or non-healing wound, ulcer, or bone fracture are not eligible for this study
+Patients with serious non-healing wound, ulcer, or bone fracture; this includes history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
+Serious, non-healing wound, ulcer, or bone fracture
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+The participant has a serious nonhealing: (a) wound, (b) peptic ulcer, or (c) bone fracture.
+Serious, non-healing wound, infection, ulcer, bone fracture, or uncontrolled seizures
+Patients with a serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment
+Patient must not have serious or non-healing wound, ulcer, or bone fracture at the time of randomization
+Major surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
+Has evidence of inadequate wound healing.
+Presence of any non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease
+Patients are excluded if they have a non-healing wound or ulcer
+Presence of non-healing wound, non-healing ulcer, or bone fracture.
+Have had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to enrollment.
+Serious non-healing wound, ulcer or bone fracture
+Patients with serous non-healing wound, ulcer, or bone fracture.
+Serious, non-healing wound, ulcer, or bone fracture requiring surgical intervention.
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Serious non-healing wound, ulcer, or bone fracture
+Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
+Non-healing wound, ulcer or bone fracture
+Presence of a non-healing wound, non-healing ulcer, or bone fracture.
+Has history of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to entry in to the trial
+Serious non-healing wound, ulcer, or bone fracture
+Serious, non-healing wound, active ulcer, or untreated bone fracture as judged by treating physician
+Serious, non-healing wound, ulcer, or bone fracture
+Patients with a history of a serious non-healing wound, ulcer, or bone fracture are not eligible
+Serious, non-healing wound, ulcer, or bone fracture
+Serious or non-healing wound, active ulcer or bone fracture
+Non-healing wound, ulcer or bone fracture
+Serious, non-healing wound, ulcer, or bone fracture as so judged by the treating physician
+Presence of a non-healing wound or non-healing ulcer that is not tumor related
+Presence of any non-healing wound, fracture, or ulcer within 28 days prior to the first dose of study drug.
+Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Non-healing wound, ulcer, or bone fracture
+Presence of any non-healing wound, fracture, or ulcer within 28 days prior to study registration.
+Has a history of non-healing wounds or ulcers, or bone refractures within 3 months of fracture
+Patients with serious non-healing wound, ulcer, or bone fracture
+Serious or non-healing wound, ulcer, or bone fracture
+Non-healing wound, ulcer, or bone fracture
+Patients with serious non-healing wound, ulcer, or bone fracture, including history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Presence of a non-healing wound or non-healing ulcer that is not tumor related
+Serious non-healing wound, ulcer, or bone fracture
+Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment
+Ongoing serious, non-healing wound, ulcer, or bone fracture
+Ongoing serious, non-healing wound, ulcer, or bone fracture
+Serious or non-healing wound, skin ulcer, or bone fracture.
+Major surgery or trauma within 28 days prior to first dose of study treatment and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
+Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
+Participants who have non-healing wound, unhealed or incompletely healed fracture, or a compound (open) bone fracture at the time of enrollment
+Prior major surgery or trauma within 28 days and/or presence of any non-healing wound, fracture or ulcer (procedures such as catheter placement not considered to be major)
+Serious non-healing wound, ulcer, or bone fracture
+Serious non-healing wound, ulcer, or bone fracture
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Patients with a serious, non-healing wound, ulcer, or bone fracture are not eligible for participation
+Non-healing wound, bone fracture or skin ulcer
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+No history of serious (i.e., requiring active medical therapy with medication or medical device under the supervision of a physician) non-healing wound, ulcer, trauma, or bone fracture within 28 days prior to study entry
+Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
+Non-healing wound, ulcer or fracture
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Serious or non-healing wound, ulcer or bone fracture
+History of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registration
+Patient must not have prior major surgery, trauma, presence of any non-healing wound, fracture, or ulcer within 28 days prior to first dose of study drug
+Non-healing wound, ulcer (including gastrointestinal), or fracture
+Serious or non-healing wound, ulcer or bone fracture; if patient develops a serious or non-healing wound, ulcer or bone fracture after enrollment, but prior to study drug initiation, patient is not eligible to begin protocol therapy
+Non-healing wound, ulcer or bone fracture
+No serious non-healing wound, ulcer or bone fracture
+Prior major surgery or trauma within 28 days prior to registration and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major); if the patient has a compression fracture secondary to tumor this should be treated and 28 days elapsed prior to entry on the protocol
+Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
+Serious, non-healing wound, active ulcer, or untreated bone fracture
+Serious or non-healing wound, ulcer, or bone fracture
+Serious, non-healing wound, active ulcer, or untreated bone fracture
+Major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer not related to cancer (procedures such as catheter placement not considered to be major)
+Other clinically significant disorders such as:\r\n* Active infection requiring systemic treatment\r\n* Serious non-healing wound/ulcer/bone fracture\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction\r\n* History of major surgery within 4 weeks or minor surgical procedures within 1 week before randomization
+History of serious or non-healing wound, ulcer, or bone fracture
+Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
+Serious, non-healing wound, active ulcer, or untreated bone fracture
+Serious, non-healing wound
+Prior major surgery or trauma within 28 days prior to first dose of pazopanib and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
+Patients with a history of non-healing wounds or ulcers, or bone refractures within 3 months of fracture
+Non-healing wound, ulcer, or bone fracture
+Patients with documented chronic non-healing wound, ulcer or bone fracture
+Serious, non-healing wound, ulcer, or bone fracture; patients with any wound requiring surgical intervention (including scalp wounds requiring cranioplasty) will be allowed to resume the study if the wound is clean and without further infection post-surgical intervention
+Subject has a serious, non-healing wound, ulcer, or bone fracture
+Serious or non-healing active wound, ulcer, or bone fracture
+Serious non-healing wound, active ulcer, or unhealed bone fracture.
+Patients with serious non-healing wound, ulcer, or untreated bone fracture. This includes a history of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1. Patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations until closure.
+Serious or non-healing wound, ulcer or bone fracture
+Serious, non-healing wound, ulcer, or bone fracture
+Serious, non-healing wound, ulcer, or bone fracture
+Non-healing wound, ulcer, or bone fracture.
+Serious non-healing wound or ulcer on scalp
+Severe acute infection; serious non-healing wound or ulcer on scalp
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Presence of a non-healing wound, non-healing skin ulcer, or bone fracture
+Presence of a non-healing wound or bone fracture
+Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
+Serious, non-healing wound, active ulcer, or untreated bone fracture
+Prior major surgery or trauma within 28 days prior to the protocol-mandated 4-week drug holiday and/or presence of any non-healing wound, fracture, or ulcer.
+Patients with a serious non-healing wound ulcer, or bone fracture, or major surgical procedure within 21 days prior to starting treatment
+Other clinically significant disorders such as:\r\n* Severe active infection requiring systemic treatment within 28 days before the first dose of study treatment\r\n* Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment\r\n* History of organ transplant\r\n* Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment (for asymptomatic patients with an elevated thyroid stimulating hormone [TSH], thyroid replacement may be initiated if clinically indicated without delaying the start of study treatment)\r\n* History of major surgery as follows:\r\n** Major surgery within 3 months of the first dose of cabozantinib; however, if there were no wound healing complications, patients with rapidly growing aggressive cancers, may start as soon as 6 weeks if wound has completely healed post-surgery\r\n** Minor surgery within 1 month of the first dose of cabozantinib if there were no wound healing complications or within 3 months of the first dose of cabozantinib if there were wound complications excluding core biopsies and Mediport placement\r\n* In addition, complete wound healing from prior surgery must be confirmed at least 28 days before the first dose of cabozantinib irrespective of the time from surgery
+Non-healing wound, ulcer, or bone fracture.
+Have a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to receiving study drugs.
+Serious, non-healing wound, ulcer, or bone fracture.
+Uncontrolled diabetes, active liver disease, poorly controlled chronic obstructive pulmonary disease, serious or non-healing wound, ulcer, or fracture;
+Serious, non-healing wound, ulcer, or bone fracture
+Severe, nonhealing or open wound, active ulcer, or untreated bone fracture
+Serious and non-healing wound, active ulcer, or untreated bone fracture.
+Non-healing wound, ulcer, or bone fracture
+Patients must not have a non-healing wound or fracture
+Presence of any non-healing wound, fracture, or ulcer
+Non-healing wound, skin ulcer, or bone fracture
+Any medical condition that requires intact wound healing capacity and is expected to endanger participant safety if wound healing capacity would be severely reduced during administration of the investigational agent
+Serious or non-healing wound, active ulcer, or untreated bone fracture
+Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Serious, non-healing wound, ulcer, or bone fracture
+Serious or non-healing active wound, ulcer, or bone fracture
+Ongoing serious non-healing wound, ulcer, or bone fracture
+Non-healing wound, ulcer (including gastrointestinal), or fracture
+Serious, non-healing wound, active ulcer, or untreated bone fracture; bone fractures must be healed
+Evidence of significant uncontrolled concomitant diseases, such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture
+Prior major surgery or trauma within 28 days prior to the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
+Serious non-healing wound, ulcer, or bone fracture
+Serious non-healing wound, ulcer, or active bone fracture;
+Serious or non-healing wound, ulcer, or bone fracture
+Has had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization
+Serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization
+Patients with serious non-healing wound, ulcer or bone fracture; this includes history of abdominal fistula or intra-abdominal abscess within 6 months; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
+Prior major surgery or trauma within 14 days of the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer
+Serious non-healing wound, ulcer, or bone fracture
+Incomplete wound healing
+A serious, non-healing wound, ulcer, or bone fracture
+Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer
+Major surgery or trauma within 29 days prior to first dose of study drug and/or presence of any non-healing wound, fracture or ulcer (catheter placement is not major surgery)
+Patients who have not recovered from the surgical resection of rectal cancer such as wound dehiscence, non-healing wound, wound infection and fistula
+Serious, non-healed wound, ulcer, or bone fracture
+No history of serious non-healing wound, ulcer, or bone fractures
+Serious, non-healing or dehiscing wound or active ulcer
+Any serious or non-healing wound, ulcer, or bone fracture
+Serious, non-healing wound, active ulcer, or unhealed bone fracture
+Presence of a non-healing wound, non-healing ulcer, or bone fracture
+Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture
+Patients with serious, non-healing wound, ulcer or bone fracture (other than pathologic fracture)
+Serious, non-healing or dehiscing wound or active ulcer
+History of recent fracture (within 3 months of recruitment), complicated non-healing fracture, hip arthroplasty, knee arthroplasty
+Patient must not have prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major)
+Patient must not have a serious or non-healing wound, ulcer, or bone fracture